Systematic Review or Meta Analysis

Nanozyme-based therapeutics are an emerging experimental strategy that aim to reduce oxidative stress and modulate immune responses in the inflamed gut — mechanisms directly relevant to IBD pathophysiology.

Oxidative stress may be a key driver of inflammation in IBD and could point to new biomarkers or adjunctive treatments (dietary changes, antioxidant strategies, or targeted pathways like Nrf2 and ferroptosis) that...

This review explains how new drug classes and mechanism-focused strategies may change how IBD is treated, which could affect choices for patients who have not responded to existing therapies and inform discussions about...

The review suggests NETs are elevated in IBD and that reducing NETs activity helped in animal models—so NETs could be a future therapeutic target and a biomarker of disease severity.

The review proposes S100B as a molecular link connecting enteric glial activation, intestinal barrier dysfunction, and liver/brain inflammation. If confirmed, this could help explain symptom overlap between gut and...

The review compiles trial and real-world safety data for upadacitinib in IBD and highlights monitoring needs and infection risks (notably herpes zoster), which are directly relevant when choosing or managing JAK...

People with IBD who have failed multiple advanced therapies are often the most difficult to treat, yet this review shows they are under-represented in clinical trials. That limits direct evidence about how well new...

Patients with refractory IBD or those not fully responding to single targeted therapies may be interested because ACT aims to control multiple inflammatory pathways and could offer improved symptom and endoscopic...

Researchers increasingly implicate innate lymphoid cells in IBD inflammation and mucosal barrier breakdown — findings that could guide future diagnostics or therapies. For patients, this helps explain research directions...

Shorter hospital stay after colorectal surgery can reduce disruption, infection risk, and costs. This review suggests ERAS pathways can shorten length of stay for people with IBD without increasing short-term...

The review suggests baseline corticosteroid use may change how well some advanced UC therapies work, especially IL-23 inhibitors and S1P modulators, which could affect treatment choices and trial reporting.

Mirikizumab showed higher rates of clinical and endoscopic remission than placebo in pooled randomized trials, which could expand treatment options for people with moderate-to-severe ulcerative colitis if confirmed by...

Perianal fistulas in Crohn’s disease are often hard to treat; this review suggests stem cell therapies can produce durable closure for many patients and appear safe over 1–4 years of follow-up.

ER stress may be a pathway connecting what people eat with intestinal inflammation in IBD. Understanding this could eventually help tailor diets or develop therapies, but human evidence is still limited.

Perianal fistulas are a common, hard-to-heal complication of Crohn's disease. This review collects current options beyond infliximab and explains where evidence is stronger or still emerging, which can help patients and...

People with IBD in remission commonly continue to have IBS-like symptoms; this review summarizes randomized trial evidence for symptom-directed treatments and finds no definitive best option.

People with IBD often need long-term advanced therapies. Cancer risk concerns commonly influence treatment choices—this review compiles current evidence to help patients and clinicians weigh risks when starting or...

This review reframes IBD as a systemic disease influenced by gut microbes, metabolism, and immune interactions — which matters because it points toward better ways to stratify patients, monitor disease, and personalize...

People with IBD may be interested because the review highlights a class of dietary polyphenols that could influence inflammation and immune pathways involved in Crohn’s disease and ulcerative colitis. It summarizes...

People with ulcerative colitis may be interested in plant-based therapies that could reduce gut inflammation or support mucosal health. This review compiles preclinical evidence suggesting Terminalia arjuna has...

This review highlights a plant-derived compound, ferulic acid, that showed anti-colitis effects in experimental studies, suggesting a potential new adjunctive therapy pathway worth watching for future clinical research.

Diet is a modifiable factor many people with IBD try to use to manage symptoms and disease; this review summarizes what is and isn’t supported by current evidence for popular diets and structured nutritional therapies.

Cure8 could only read part of this source from INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, so this card uses cautious topic tags instead of a full summary. It is tagged...

This pooled analysis compares serious-infection and sepsis risks across advanced therapies used in immune-mediated inflammatory diseases, including IBD. It suggests JAK inhibitors are linked to higher serious-infection...

The review highlights marine polysaccharides as multi-target agents that could modulate inflammation, the microbiome, and the gut barrier—processes central to ulcerative colitis—and points to possible roles as functional...

Based on the title and source metadata, this appears to be a systematic review or meta analysis related to Inflammatory bowel disease and Research and clinical trials. The original article is from Indian Journal of...

Dietary macronutrients affect microbiota, barrier integrity, and mucosal immunity in ways that could alter IBD activity. Understanding these pathways could inform more targeted dietary strategies beyond generic...

Extracellular vesicle (EV) therapies are being explored as new ways to modulate immune responses and promote mucosal repair in IBD, which could eventually expand treatment options beyond current biologics and small...

Trial design affects how quickly and reliably new IBD treatments are tested and approved, and can influence patient experience (placebo exposure, retention) and whether trial populations reflect real-world patients.

If lymphatic dysfunction helps cause or sustain Crohn’s inflammation, it could explain some classic disease features (patchy, transmural inflammation and mesenteric changes) and point to new treatment approaches aimed at...

IL-23 inhibitors are a newer class of biologics for moderate-to-severe ulcerative colitis that may offer another effective option for patients who have not responded to existing therapies, with improving evidence for...

Based on the title and source metadata, this appears to be a systematic review or meta analysis related to Inflammatory bowel disease and Research and clinical trials. The original article is from Frontiers in...

AI tools for endoscopic and multimodal IBD assessment could make scoring and monitoring more objective and consistent, which matters for treatment decisions and tracking remission or relapse. The review also flags...

People with IBD may be concerned about environmental exposures that could influence inflammation or worsen disease. This review explains why micro- and nanoplastics are biologically plausible contributors but also why...

This meta-analysis pulls together early trial evidence that TL1A antagonists may improve clinical, endoscopic, and histologic outcomes in both UC and CD and reports an overall acceptable short-term safety...

New oral micro- and nanomedicine strategies aim to deliver drugs more selectively to diseased areas in the gut, which could eventually improve treatments for IBD and colorectal cancer by increasing local effects and...

miRNAs are being studied as stable circulating biomarkers and possible therapeutic targets in immune diseases including IBD. Advances could eventually improve earlier diagnosis, track disease course, or lead to new...

Cocaine use can trigger severe GI problems that mimic common surgical and inflammatory conditions; recognizing the link can speed diagnosis and management. Most published evidence is low-level (case reports/series), so...

SMC phenotypic switching can contribute to intestinal fibrosis and motility problems in IBD; understanding macrophage regulation of SMCs could point to new treatment targets for these complications.

NOD2 loss-of-function is a major genetic risk for Crohn’s disease, and this review highlights that gut microbes can modulate NOD2 signaling. That connection may help explain variation in disease risk and points to...

Patients and clinicians using vedolizumab may be interested because the review links higher trough concentrations to better remission outcomes—most convincingly for endoscopic remission in UC—and provides descriptive...

The exposome perspective emphasizes that many non-genetic, potentially modifiable environmental factors likely influence IBD risk. Understanding these factors could help guide prevention research and public-health...

The review suggests that specific Klebsiella pneumoniae strains could connect chronic IBD inflammation with rectal cancer risk, pointing to possible biomarker or prevention targets that may be relevant for people with...

Single-cell and spatial multi-omics help explain why many patients do not respond to current biologics and JAK inhibitors and point toward molecular and cellular biomarkers that could one day guide more precise treatment...

Spatially resolved profiling could identify the specific cell neighborhoods and signaling circuits that drive disease in a person’s gut tissue, which may help predict who will respond to particular biologics or small...

Based on the title and source metadata, this appears to be a systematic review or meta analysis related to Ulcerative colitis, Colorectal cancer, and Diet and lifestyle. The original article is from Food science &...

Based on the title and source metadata, this appears to be a systematic review or meta analysis related to Inflammatory bowel disease and Mental health and quality of life. The original article is from Cureus.

The analysis compares rescue drugs used when severe ulcerative colitis doesn't respond to IV steroids — a high-stakes situation where avoiding colectomy matters.